Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MoonLake Immunotherapeutics filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing sonelokimab (SLK) for inflammatory diseases. Form 8-K reports cover operating and financial results, clinical-trial disclosures for SLK programs, FDA meeting updates, Regulation FD communications, material agreements and capital-structure matters involving Class A ordinary shares.
Proxy materials describe annual meeting voting matters, including director elections, auditor ratification, executive compensation and amendments to the 2022 Equity Incentive Plan. The filing record also includes exhibits and registration-related disclosures tied to financings, governance matters and shareholder approvals.
MoonLake Immunotherapeutics reports that Cormorant Asset Management, LP and Bihua Chen together beneficially own 4,480,433 Class A ordinary shares, equal to 6.25% of the Class A shares outstanding. The percentage is calculated using 71,727,875 shares outstanding as of February 1, 2026.
The filing states the holders have shared voting and dispositive power over the 4,480,433 shares. The statement is an amendment to an earlier joint filing and is signed by Bihua Chen.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 13,653 Class A ordinary shares in an open-market transaction. The shares were sold at a weighted average price of about $20.02 per share across multiple trades between $19.50 and $20.83. After this sale, he directly holds 1,172,431 Class A ordinary shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed opportunistically.
MoonLake Immunotherapeutics reported a larger net loss for the quarter ended March 31, 2026 as it continued to invest heavily in its Sonelokimab (SLK) pipeline. Net loss was $69.7 million, compared with $40.6 million a year earlier, driven mainly by higher research and development spending of $54.5 million.
The company ended the quarter with $298.5 million in cash and cash equivalents and $59.4 million in short-term marketable debt securities, and stated this, together with recent equity proceeds, should fund operations to the end of 2027. Long-term debt rose to $99.0 million after drawing a second tranche under its $500.0 million secured term loan facility.
Clinically, MoonLake highlighted continued positive Phase 3 data for SLK in hidradenitis suppurativa, supportive FDA feedback that its existing HS trials can establish substantial evidence of effectiveness, and progress across Phase 3 psoriatic arthritis and Phase 2 programs in palmoplantar pustulosis and axial spondyloarthritis, alongside preparation for a planned HS biologics license application submission in the third quarter of 2026.
MoonLake Immunotherapeutics reported a larger net loss but also a key regulatory milestone for its lead drug sonelokimab. For the quarter ended March 31, 2026, the company posted a net loss of $69.7 million, or $0.98 per share, on operating expenses of $70.0 million.
MoonLake ended the quarter with $357.9 million in cash, cash equivalents and short-term marketable debt securities and expects this to fund operations to the end of 2027, supplemented by up to $400 million available from a debt facility. Total assets were $400.4 million and shareholders’ equity was $254.0 million.
The FDA gave a positive outcome in the final pre-BLA meeting for sonelokimab in hidradenitis suppurativa, agreeing on submission plans, label strategy and use of MIRA and VELA-TEEN data. MoonLake plans to submit a Biologics License Application by the end of September 2026, with a potential first U.S. launch in the second half of 2027 if approved.
MoonLake Immunotherapeutics is asking shareholders to vote at its 2026 Annual General Meeting on June 4, 2026 in New York. Shareholders will elect Class I director nominee Spike Loy, ratify Baker Tilly US, LLP as independent auditor for 2026, and cast an advisory say-on-pay vote on executive compensation.
The key item is approval of an amended and restated 2022 Equity Incentive Plan. The plan would add 5,000,000 Class A Ordinary Shares for awards, bringing the total share pool to 9,353,948 and representing potential dilution of about 6.2% as of April 1, 2026. It also extends the plan term to June 4, 2036, adds a one-year minimum vesting requirement (with limited exceptions), adjusts non-employee director compensation limits, removes liberal share recycling, and clarifies change-in-control treatment.
As of the April 9, 2026 record date, there were 72,852,170 Class A Ordinary Shares outstanding, each entitled to one vote. The proxy describes MoonLake’s governance framework, board and committee structure, director independence, and executive pay philosophy. The Compensation Committee notes 99% support for the prior say-on-pay vote and that named executive officers waived 2025 cash bonuses despite achieving corporate goals.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 2,426 Class A ordinary shares in an open-market transaction. The shares were sold on April 14, 2026 at a weighted average price of $19.56 per share, in multiple trades between $19.50 and $19.625.
After this transaction, he directly holds 1,186,084 Class A ordinary shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed discretionarily.
MoonLake Immunotherapeutics Chief Executive Officer Jorge Santos da Silva reported open-market sales of 150,000 Class A ordinary shares of the company. The transactions occurred on April 10 and April 13 at weighted average prices of $18.41 and $18.23 per share, respectively, in multiple trades within disclosed price ranges. Following these sales, he continues to hold 2,924,893 Class A ordinary shares directly. The sales were made pursuant to Rule 144 under the Securities Act, indicating resales of already-owned shares under an established exemption.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025 to cover his tax liabilities.
He sold 85,870 shares on April 9, 2026 at a weighted average price of $18.94 per share and 1,925 shares on April 10, 2026 at a weighted average price of $19.51 per share, for total reported sales of 87,795 shares. Following these transactions, he directly holds 1,188,510 Class A ordinary shares.
MoonLake Immunotherapeutics submitted a Form 144 notice concerning proposed sales of Class A common shares. The filing lists a 150,000 share figure alongside account and outstanding figures and shows 3,027,483 shares obtained upon exchange on 10/01/2023.
The filing names UBS Financial Services Inc. as the broker and includes a filing date of 04/10/2026. The excerpt does not state prices, planned sale timing, or proceeds treatment.